{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:39Z","timestamp":1792012899370,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Pfizer (US)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12969-017-0212-y","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T19:47:41Z","timestamp":1514404061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study"],"prefix":"10.1186","volume":"15","author":[{"name":"for the Pediatric Rheumatology International Trials Organization (PRINTO)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pediatric Rheumatology Collaborative Study Group (PRCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Tzaribachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Smolewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Vehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Mebus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Alvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Krishnaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"212_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"212_CR2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767\u201378.","journal-title":"Lancet"},{"key":"212_CR3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112\u20137.","journal-title":"Joint Bone Spine"},{"key":"212_CR4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3899\/jrheum.120661","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996\u20132009. J Rheumatol. 2013;40:1218\u201325.","journal-title":"J Rheumatol"},{"key":"212_CR5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/art.1780390817","volume":"39","author":"LS Peterson","year":"1996","unstructured":"Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960\u20131993. Is the epidemiology changing? Arthritis Rheum. 1996;39:1385\u201390.","journal-title":"Arthritis Rheum"},{"key":"212_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40744-016-0040-4","volume":"3","author":"G Giancane","year":"2016","unstructured":"Giancane G, Consolaro A, Lanni S, Davi S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3:187\u2013207.","journal-title":"Rheumatol Ther"},{"key":"212_CR7","first-page":"379","volume":"6","author":"EJ Oberle","year":"2014","unstructured":"Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol. 2014;6:379\u201393.","journal-title":"Clin Epidemiol"},{"key":"212_CR8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499\u2013512.","journal-title":"Arthritis Rheum"},{"key":"212_CR9","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med"},{"key":"212_CR10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med"},{"key":"212_CR11","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum"},{"key":"212_CR12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383\u201391.","journal-title":"Lancet"},{"key":"212_CR13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465\u201382.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"212_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2009.03570.x","volume":"69","author":"S Cohen","year":"2010","unstructured":"Cohen S, Zwillich SH, Chow V, LaBadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010;69:143\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"212_CR15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42:759\u201373.","journal-title":"Drug Metab Dispos"},{"key":"212_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10928-007-9080-2","volume":"35","author":"MM Hutmacher","year":"2008","unstructured":"Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35:139\u201357.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"212_CR17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0091270008330982","volume":"49","author":"N Lawendy","year":"2009","unstructured":"Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol. 2009;49:423\u20139.","journal-title":"J Clin Pharmacol"},{"key":"212_CR18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/adc.2010.188946","volume":"96","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric rheumatology international trials organisation (PRINTO). Arch Dis Child. 2011;96:596\u2013601.","journal-title":"Arch Dis Child"},{"key":"212_CR19","first-page":"S1","volume":"19","author":"N Ruperto","year":"2001","unstructured":"Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19:S1\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"212_CR20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970\u201381.","journal-title":"Arthritis Rheum"},{"key":"212_CR21","unstructured":"Center for Drug Evaluation and Research [CDER]. Clinical pharmacology review NDA 203214. 2011. \nhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000ClinPharmR.pdf\n\n. Accessed 19 Dec 2017."},{"key":"212_CR22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253\u201362.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-017-0212-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T19:47:55Z","timestamp":1514404075000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-017-0212-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s12969-017-0212-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"86"}}